Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label study of SAR443579 in relapsed or refractory AML, B-ALL, HR-MDS, or BPDCN
jRCT2031240490Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of SAR443579 in acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B-ALL), myelodysplastic syndrome (MDS) and 1 more (2 arms), sponsored by Sanofi. Primary endpoints: Incidence of dose-limiting toxicity in escalation part, Incidence of dose-limiting toxicity in Japanese participants and 2 more. Started Feb 2025; status: completed.
02
Drugs
SAR443579
03
Conditions
acute myeloid leukemia (AML)B cell acute lymphoblastic leukemia (B-ALL)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on jRCT2031240490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240490.